PE20120032A1 - Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamida - Google Patents
Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamidaInfo
- Publication number
- PE20120032A1 PE20120032A1 PE2011001059A PE2011001059A PE20120032A1 PE 20120032 A1 PE20120032 A1 PE 20120032A1 PE 2011001059 A PE2011001059 A PE 2011001059A PE 2011001059 A PE2011001059 A PE 2011001059A PE 20120032 A1 PE20120032 A1 PE 20120032A1
- Authority
- PE
- Peru
- Prior art keywords
- oil
- pharmaceutical composition
- weight
- sterfat
- total composition
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 abstract 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 abstract 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 1
- 229920002675 Polyoxyl Polymers 0.000 abstract 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940113088 dimethylacetamide Drugs 0.000 abstract 1
- 239000001087 glyceryl triacetate Substances 0.000 abstract 1
- 235000013773 glyceryl triacetate Nutrition 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229960002622 triacetin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (A) UN COMPUESTO DE FORMULA (1) EN UNA CANTIDAD DE 1-40% DE PESO DE LA COMPOSICION TOTAL; (B) UN TENSOACTIVO QUE TIENE UN EQUILIBRIO HIDROFILO/LIPOFILO MAYOR QUE 10 TAL COMO VITAMINA E TPGS, ACEITE DE RICINO POLIETOXILADO, ACEITE DE RICINO HIDROGENADO DE POLIOXILO, ESTER GRASO DE POLIOXIETILEN-SORBITAN, MACROGOLGLICERIDO DE CAPRILOCAPROILO O SUS MEZCLAS EN CANTIDAD DE 2-50% EN PESO DE LA COMPOSICION TOTAL (C) AL MENOS UN DISOLVENTE QUE COMPRENDA DE 10-90% EN PESO DE LA COMPOSICION TOTAL TAL COMO PROPILENGLICOL, POLIPROPILENGLICOL, POLIETILENGLICOL CON PESO MOLECULAR MAYOR QUE 300 Y MENOR QUE 600 , GLICEROL, ETANOL, TRIACETIN, DIMETIL ISOSORBIDA, GLICOFUROL, CARBONATO DE PROPILENO, AGUA, DIMETIL-ACETAMIDA O SUS MEZCLAS. DICHA COMPOSICION FARMACEUTICA NO CONTIENE LIPIDOS. LA COMPOSICION FARMACEUTICA SE ENCUENTRA EN FORMA LIQUIDA FACILITANDO SU ADMINISTRACION EN FORMA ORAL SIENDO UN INHIBIDOR VIRAL DE LA HEPATITIS C
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11678908P | 2008-11-21 | 2008-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120032A1 true PE20120032A1 (es) | 2012-02-12 |
Family
ID=41650279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001059A PE20120032A1 (es) | 2008-11-21 | 2009-11-18 | Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamida |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20120101049A1 (es) |
| EP (1) | EP2358355B1 (es) |
| JP (1) | JP5553839B2 (es) |
| KR (1) | KR20110087297A (es) |
| CN (1) | CN102223875A (es) |
| AR (1) | AR074391A1 (es) |
| AU (1) | AU2009316755B2 (es) |
| BR (1) | BRPI0921070A2 (es) |
| CA (1) | CA2738732A1 (es) |
| CL (1) | CL2011000878A1 (es) |
| CO (1) | CO6361900A2 (es) |
| CY (1) | CY1114892T1 (es) |
| DK (1) | DK2358355T3 (es) |
| EA (1) | EA022272B1 (es) |
| EC (1) | ECSP11011065A (es) |
| ES (1) | ES2445516T3 (es) |
| HR (1) | HRP20140097T1 (es) |
| IL (1) | IL211832A (es) |
| MA (1) | MA32812B1 (es) |
| ME (1) | ME01614B (es) |
| MX (1) | MX2011005151A (es) |
| MY (1) | MY155402A (es) |
| NZ (1) | NZ592383A (es) |
| PE (1) | PE20120032A1 (es) |
| PL (1) | PL2358355T3 (es) |
| PT (1) | PT2358355E (es) |
| RS (1) | RS53121B (es) |
| SG (1) | SG171771A1 (es) |
| SI (1) | SI2358355T1 (es) |
| TN (1) | TN2011000258A1 (es) |
| TW (1) | TWI469801B (es) |
| UA (1) | UA105777C2 (es) |
| UY (1) | UY32252A (es) |
| WO (1) | WO2010059667A1 (es) |
| ZA (1) | ZA201102029B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| SG177569A1 (en) | 2009-07-07 | 2012-03-29 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| US20120135949A1 (en) | 2010-09-30 | 2012-05-31 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection |
| EA201390532A1 (ru) * | 2010-10-08 | 2013-09-30 | Новартис Аг | Композиции сульфамидых ингибиторов ns3, содержащие витамин е |
| MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
| MX2013007698A (es) | 2010-12-30 | 2013-08-15 | Abbvie Inc | Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina. |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AP2014007760A0 (en) * | 2012-01-12 | 2014-07-31 | Boehringer Ingelheim Int | Stabilized pharmaceutical formulations of a potentHCV inhibitor |
| JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法 |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| WO2013169577A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| EA029088B1 (ru) | 2013-03-15 | 2018-02-28 | Джилид Сайэнс, Инк. | Макроциклические и бициклические ингибиторы вируса гепатита c |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2466851C (en) * | 2001-11-26 | 2012-09-11 | Supergen, Inc. | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| PE20050204A1 (es) * | 2003-05-21 | 2005-05-04 | Boehringer Ingelheim Int | Compuestos inhibidores de la hepatitis c |
| CA2568008C (en) * | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic hcv protease inhibitors |
-
2009
- 2009-11-18 HR HRP20140097AT patent/HRP20140097T1/hr unknown
- 2009-11-18 DK DK09760395.5T patent/DK2358355T3/da active
- 2009-11-18 AU AU2009316755A patent/AU2009316755B2/en not_active Expired - Fee Related
- 2009-11-18 EA EA201100795A patent/EA022272B1/ru not_active IP Right Cessation
- 2009-11-18 CA CA2738732A patent/CA2738732A1/en not_active Abandoned
- 2009-11-18 UA UAA201107610A patent/UA105777C2/uk unknown
- 2009-11-18 SG SG2011036498A patent/SG171771A1/en unknown
- 2009-11-18 PL PL09760395T patent/PL2358355T3/pl unknown
- 2009-11-18 CN CN2009801464655A patent/CN102223875A/zh active Pending
- 2009-11-18 RS RS20130583A patent/RS53121B/sr unknown
- 2009-11-18 EP EP09760395.5A patent/EP2358355B1/en active Active
- 2009-11-18 MY MYPI2011002269A patent/MY155402A/en unknown
- 2009-11-18 MX MX2011005151A patent/MX2011005151A/es active IP Right Grant
- 2009-11-18 KR KR1020117011446A patent/KR20110087297A/ko not_active Withdrawn
- 2009-11-18 ES ES09760395.5T patent/ES2445516T3/es active Active
- 2009-11-18 NZ NZ592383A patent/NZ592383A/xx not_active IP Right Cessation
- 2009-11-18 ME MEP-2013-140A patent/ME01614B/me unknown
- 2009-11-18 BR BRPI0921070A patent/BRPI0921070A2/pt not_active IP Right Cessation
- 2009-11-18 WO PCT/US2009/064908 patent/WO2010059667A1/en not_active Ceased
- 2009-11-18 SI SI200930810T patent/SI2358355T1/sl unknown
- 2009-11-18 JP JP2011537562A patent/JP5553839B2/ja not_active Expired - Fee Related
- 2009-11-18 PT PT97603955T patent/PT2358355E/pt unknown
- 2009-11-18 PE PE2011001059A patent/PE20120032A1/es not_active Application Discontinuation
- 2009-11-18 US US13/129,641 patent/US20120101049A1/en not_active Abandoned
- 2009-11-20 TW TW98139549A patent/TWI469801B/zh not_active IP Right Cessation
- 2009-11-20 AR ARP090104496A patent/AR074391A1/es unknown
- 2009-11-20 UY UY0001032252A patent/UY32252A/es not_active Application Discontinuation
-
2011
- 2011-03-17 ZA ZA2011/02029A patent/ZA201102029B/en unknown
- 2011-03-21 IL IL211832A patent/IL211832A/en not_active IP Right Cessation
- 2011-04-19 CL CL2011000878A patent/CL2011000878A1/es unknown
- 2011-05-20 MA MA33867A patent/MA32812B1/fr unknown
- 2011-05-20 TN TN2011000258A patent/TN2011000258A1/fr unknown
- 2011-05-20 EC EC2011011065A patent/ECSP11011065A/es unknown
- 2011-05-24 CO CO11063891A patent/CO6361900A2/es not_active Application Discontinuation
-
2014
- 2014-01-24 CY CY20141100063T patent/CY1114892T1/el unknown
- 2014-10-17 US US14/517,242 patent/US20150038532A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120032A1 (es) | Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamida | |
| CO6341565A2 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
| CR9587A (es) | Derivados de piridazina | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| TW200626558A (en) | Indazolone derivatives | |
| AR061134A1 (es) | Derivados de tioxantina | |
| ECSP055774A (es) | Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica | |
| CU20080235A7 (es) | Composiciones farmacéuticas estabilizadas que comprenden fesoterodina | |
| MX356957B (es) | Analogos del glucagon. | |
| PE20160605A1 (es) | Formulaciones de inhibidores de la syk | |
| AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
| ECSP10010167A (es) | Composiciones oftálmicas novedosas | |
| PA8783401A1 (es) | Derivados de piperidina/piperazina | |
| ECSP11011555A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
| RU2009138047A (ru) | Стабилизация витамина в12 | |
| ECSP088229A (es) | Derivados de pirazolona como inhibidores de 11-beta hsd1 | |
| CO6321158A2 (es) | Formulacion oral | |
| ECSP088689A (es) | NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS | |
| DOP2012000050A (es) | Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| CO6501175A2 (es) | Derivados de benzotiazinas, su preparación y aplicación como fármacos | |
| WO2010105951A3 (en) | Composition comprising the combination of madecassoside, of an arginine and of polysorbate | |
| MX2009003169A (es) | Derivados de sulfonamida. | |
| MX338801B (es) | Composiciones de cuidado oral. | |
| WO2009083664A8 (fr) | Nouvelles compositions a base de taxoides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |